ClinicalTrials.gg
CompletedNCT00508820Updated Nov 14, 2022Results posted

An Open Label Study of Romiplostim in Adult Thrombocytopenic Subjects With ITP

A Phase 3 interventional study of Romiplostim in Idiopathic Thrombocytopenic Purpura, Thrombocytopenia and Thrombocytopenic Purpura, sponsored by Amgen. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-11-14.

Sponsored by Amgen · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 2 years 5 months after the study started (first participant enrolled Feb 2005, registered Jul 2007).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
407
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 29 studies testing romiplostim in Purpura, Thrombocytopenic, Idiopathic — 5 open to participants now, 6 under way, 2 of them phase 3. romiplostim · Purpura, Thrombocytopenic, Idiopathic.

Enrollment
2nd of 29
407 · median 62
Started
2005
with 2 others
Phase 3
13 of 29
1 open now
Registered
8th of 29
by date
Lead sponsor
14 of 29
Amgen

Among the 29 studies testing romiplostim in Purpura, Thrombocytopenic, Idiopathic, this one is the 2nd largest by enrollment, is one of 3 that started in 2005, is one of 13 in phase 3, and was the 8th registered.

Purpura, Thrombocytopenic, Idiopathic

504 studies on the registry are indexed under Purpura, Thrombocytopenic, Idiopathic; 159 are open to participants now.

Browse Purpura, Thrombocytopenic, Idiopathic studies →

Open to participants now

5 of the 29 studies testing romiplostim in Purpura, Thrombocytopenic, Idiopathic are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About romiplostim

romiplostim: first FDA approval 2008 (NPLATE), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 103 Purpura, Thrombocytopenic, Idiopathic studies recruiting now, 49 (48%) set no upper age limit and 42 (41%) stop at 75 or younger; 27 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies testing romiplostim in Purpura, Thrombocytopenic, Idiopathic, or all of them as a file.
02

Study summary

This protocol will provide open label romiplostim to adult thrombocytopenic subjects. Romiplostim will be administered by subcutaneous injection once per week. Dose adjustment will be based on platelet counts, and will be allowed throughout the duration of the study. Rescue therapies are allowed at any time during the study. Reductions in concurrent ITP therapies may occur at any time when platelet counts are > 50,000.

03

Conditions studied

  • Idiopathic Thrombocytopenic Purpura
  • Thrombocytopenia
  • Thrombocytopenic Purpura

Keywords

  • Platelet
  • AMG 531
  • Thrombopoietin
  • blood disorder
  • bleeding disorder
  • immune thrombocytopenic purpura
  • idiopathic thrombocytopenic purpura
  • immune (idiopathic) thrombocytopenic purpura
  • TPO
  • thrombopoietic protein
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject is ≥ 18 years of age
  • Subject has a diagnosis of immune (idiopathic) thrombocytopenic purpura per the American Society of Hematology guidelines
  • If Subject is > 60 years of age, subject has a written bone marrow aspiration and/or report consistent with a diagnosis of ITP
  • Subject has received at least 1 prior therapy for ITP
  • Subject's count is ≤ 30,000 or the subject is experiencing bleeding that is uncontrolled with conventional therapies
  • Subject (or legally-acceptable representative) is willing and able to provide written

Exclusion criteria

Exclusion Criteria:

  • Subject has a history of hematological , myeloproliferative disorder, myelodysplastic syndrome (MDS), or bone marrow stem cell disorder
  • Subject has participated in any study evaluating PEG-rHuMGDF, recombinant human thrombopoietin (rHuTPO), or related product
  • Subject has a known to any recombinant E coli-derived product
  • Subject has received any therapeutic drug or device that is not approved by the local regulatory health agency for any indication within 4 weeks of Screening
  • Subject is of and is not using adequate precautions, in the judgment of the investigator
  • Subject is pregnant or breast feeding
  • Investigator has concerns regarding the subject's ability to comply with the protocol procedures
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
407 participants (actual)

Study arms

  • Experimental
    1

    Romiplostim

    Biological: Romiplostim

Interventions

  • BiologicalRomiplostim

    Romiplostim will be administered subcutaneously QW. Romiplostim will be manufactured and packaged and distributed using Amgen's clinical study investigational product distribution procedures. Romiplostim is presented as a lyophilized, white powder in 5.0 mL glass vials.

06

What researchers measure

Primary outcomes

  1. Adverse Events

    One or more occurences of one or more adverse events within the participant during the study. Participants with more than one event were only counted once

    Time frame: Duration of Treatment plus 30 days or End of Study (whichever is later). Approximately 205 weeks.

Secondary outcomes

  1. Platelet Response (Definition 1)

    Platelet response using definition1 . (a doubling of baseline platelet count and a platelet count of \>=50 x 10\^9/L

    Time frame: Duration of treatment (up to 201 weeks)

  2. Platelet Response (Definition 2)

    Platelet response using definition 2 (a platelet count increase of \>=20 x 109/L from baseline)

    Time frame: Duration of treatment (up to 201 weeks)

07

Results

Posted Feb 13, 2012

Participant flow

First Subject Enrolled: 24Feb2005 Last Subject Enrolled: 05Jan2010

Participant flow — Overall Study
MilestoneRomiplostim (AMG 531) Cohort 1Romiplostim (AMG 531) Cohort 2
Started168239
Completed113175
Not completed5564
Withdrew: Adverse event610
Withdrew: Death68
Withdrew: Lost to follow-up11
Withdrew: Physician decision82
Withdrew: Pregnancy02
Withdrew: Protocol violation20
Withdrew: Withdrawal by subject1012
Withdrew: Other112
Withdrew: Noncompliance10
Withdrew: Requirement for alternative therapy715
Withdrew: Protocol-specified criteria312

Outcome measures

PrimaryAdverse Events

One or more occurences of one or more adverse events within the participant during the study. Participants with more than one event were only counted once

Time frame:
Duration of Treatment plus 30 days or End of Study (whichever is later). Approximately 205 weeks.
Reported as:
Number · participants
Adverse Events
participantsRomiplostim (AMG 531) Cohort 1Romiplostim (AMG 531) Cohort 2
Adverse Events162215
SecondaryPlatelet Response (Definition 1)

Platelet response using definition1 . (a doubling of baseline platelet count and a platelet count of \>=50 x 10\^9/L

Time frame:
Duration of treatment (up to 201 weeks)
Reported as:
Number · Participants
Platelet Response (Definition 1)
ParticipantsRomiplostim (AMG 531) Cohort 1Romiplostim (AMG 531) Cohort 2
Platelet Response (Definition 1)156214
SecondaryPlatelet Response (Definition 2)

Platelet response using definition 2 (a platelet count increase of \>=20 x 109/L from baseline)

Time frame:
Duration of treatment (up to 201 weeks)
Reported as:
Number · Participants
Platelet Response (Definition 2)
ParticipantsRomiplostim (AMG 531) Cohort 1Romiplostim (AMG 531) Cohort 2
Platelet Response (Definition 2)160220

Adverse events

Collected over Average duration: cohort 1 52 wks; cohort 2 42 wks.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Romiplostim Cohort 1—61/168 (36.3%)155/168 (92.3%)
Romiplostim Cohort 2—61/239 (25.5%)188/239 (78.7%)
Most frequent serious events
Showing 10 of 166
Most frequent serious events
EventRomiplostim Cohort 1Romiplostim Cohort 2
ThrombocytopeniaBlood and lymphatic system disorders10/16810/239
PneumoniaInfections and infestations6/1683/239
Idiopathic thrombocytopenic purpuraBlood and lymphatic system disorders5/1682/239
Gastrointestinal haemorrhageGastrointestinal disorders5/1680/239
EpistaxisRespiratory, thoracic and mediastinal disorders5/1683/239
Pulmonary embolismRespiratory, thoracic and mediastinal disorders5/1681/239
Urinary tract infectionInfections and infestations3/1680/239
Acute respiratory distress syndromeRespiratory, thoracic and mediastinal disorders3/1680/239
PurpuraSkin and subcutaneous tissue disorders3/1681/239
Deep vein thrombosisVascular disorders3/1681/239
Most frequent other events
Showing 10 of 50
Most frequent other events
EventRomiplostim Cohort 1Romiplostim Cohort 2
HeadacheNervous system disorders57/16861/239
FatigueGeneral disorders50/16825/239
ArthralgiaMusculoskeletal and connective tissue disorders46/16834/239
ContusionInjury, poisoning and procedural complications39/16821/239
NasopharyngitisInfections and infestations38/16831/239
CoughRespiratory, thoracic and mediastinal disorders35/16822/239
EpistaxisRespiratory, thoracic and mediastinal disorders34/16831/239
DiarrhoeaGastrointestinal disorders33/16824/239
NauseaGastrointestinal disorders32/16838/239
PetechiaeSkin and subcutaneous tissue disorders29/16831/239

Baseline characteristics

Age, Continuous
Age, Continuous(years)Romiplostim (AMG 531) Cohort 1Romiplostim (AMG 531) Cohort 2Total
Mean53.6 ± 1754.1 ± 1853.9 ± 17.6
Sex: Female, Male
Sex: Female, Male(Participants)Romiplostim (AMG 531) Cohort 1Romiplostim (AMG 531) Cohort 2Total
Female94150244
Male7489163
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Romiplostim (AMG 531) Cohort 1Romiplostim (AMG 531) Cohort 2Total
White or Caucasian149232381
Black or African American516
Hispanic or Latino729
Asian538
Other112
Native Hawaiian or Other Pacific Islander101
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Janssens A, Tarantino M, Bird RJ, Mazzucconi MG, Boccia RV, Fernandez MF, Kozak T, Steurer M, Boekhorst Pt, Dillingham K, Kreuzbauer G, Woodard P. Romiplostim Treatment in Adults with Immune Thrombocytopenia of Varying Duration and Severity. Acta Haematol. 2015;134(4):215-28. doi: 10.1159/000381657. PubMed 26066765 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2005 to primary completion in Jan 2011, 71 months.

Results were first posted in Feb 2012, 1 year 1 month after primary completion.

Of 41 industry-sponsored phase 3 interventional studies under Purpura, Thrombocytopenic, Idiopathic, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 44. This study's 71 months is above that.

Counting every sponsor, half of 57 studies reached it within 28 months; a quarter within 22 and three quarters within 49.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 26, 2007
First posted
Jul 30, 2007
StartActual
Feb 1, 2005
Primary completionActual
Jan 1, 2011
CompletionActual
Mar 1, 2011
Results first posted
Feb 13, 2012
Last update
Nov 14, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 14, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00508820
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Jul 30, 2007
Start date
Feb 1, 2005
Primary completion
Jan 1, 2011
Completion
Mar 1, 2011
Results posted
Feb 13, 2012
Last update
Nov 14, 2022

Study contacts

MD
study director · Amgen
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Romiplostim

Start the discussion